|  |  |  |
| --- | --- | --- |
| **Table S1. Baseline characteristics of patients excluded from primary analysis** | | |
|  | **Traditional dosing**  **(n = 27)** | **Genotype-guided dosing**  **(n = 26)** |
| Age, mean (SD), y | 59.5 (14.0) | 60.3 (14.9) |
| Weight, mean (SD), kg | 60.4 (14.6) | 64.2 (14.1) |
| Race, No. | | |
| * Chinese | 18/27 | 16/26 |
| * Malay | 4/27 | 4/26 |
| * Indian | 3/27 | 1/26 |
| * Others | 2/27 | 5/26 |
| *CYP2C9* genotype, No./total | | |
| * Presence of \*3 allele | 1/26 | 2/26 |
| *VKORC1* -381 genotype, No./total | | |
| * C/C | 9/27 | 19/26 |
| * C/T | 13/27 | 6/26 |
| * T/T | 5/27 | 1/26 |
| Indication, No./total |  |  |
| * Atrial fibrillation | 3/26 | 12/24 |
| * Stroke | 2/26 | 1/24 |
| * Deep vein thrombosis | 9/26 | 5/24 |
| * Pulmonary embolism | 2/26 | 3/24 |
| * Left ventricular thrombus | 3/26 | 1/24 |
| * Others | 5/26 | 4/24 |
| Amiodarone, No./total | 0/26 | 3/24 |
| LMWH, No./total | 12/26 | 8/25 |
| Medical history, No./total |  |  |
| * Stroke | 1/26 | 3/25 |
| * Deep vein thrombosis | 3/26 | 0/25 |
| * Pulmonary embolism | 1/26 | 0/25 |
| * Myocardial infarction | 1/26 | 4/25 |
| * Congestive heart failure | 2/26 | 3/25 |
| * Hypertension | 12/26 | 14/25 |
| Type 2 diabetes mellitus | 9/26 | 10/25 |
|  | | |